Proveca focuses on the re-engineering of existing generic medicines to make them appropriate for use by young people. The company is currently developing a commercialisng medicines for children in the fields of cardiology, neurology and pain management.
Albion portfolio company Proveca has received a positive opinion from the EMA CHMP on their lead compound Sialanar
Proveca gains fourth key agreement with EMA
ALBION VENTURES INVESTS £2.6M IN PHARMA FIRM PROVECA
PROVECA GAINS FOURTH KEY AGREEMENT WITH EMA